Maarten Kraaijenhagen is a medical doctor with several years of clinical experience in the field of acute medicine, general surgery and orthopedic surgery and over 13 years of experience working as a Pharmaceutical Physician. He started his pharmaceutical career working for Wyeth and transitioned to Pfizer in 2010. He’s currently working as a Senior Medical Director within Rare Diseases.
His main responsibilities are to provide medical input on rare diseases and to ensure the continuous generation of new data on rare diseases, through clinical studies. Furthermore his role is to ensure that patients, health care professionals and colleagues are optimally informed and educated on the (safe use of) orphan drugs that Pfizer develops and produces.
Pfizer is a consortium member of Project PARADIGM which stands for “Patients Active in Research And Dialogues for an Improved Generation of Medicines.” PARADIGM is an Innovative Medicines Initiative (IMI), which is a partnership between the European Union and the European pharmaceutical industry association EFPIA.
This project is led by the European Patients’ Forum (EPF) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The 34 consortium members include representatives from patient organizations, regulatory bodies, academia, non-profit organizations, trade associations, and pharmaceutical companies, along with subject matter experts.